Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000087

Chief Executive Officer sold 75,000 shares at an average $91.83 ($6,887,484)

  • Chief Executive Officer acquired 75,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Klein Lawrence Otto · Chief Executive Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2026-09-01 Exercise or conversion : show line 1 in the form 10b5-1 +75,000 $7.80 $585,000 1,000,580 D
2026-09-01 Sale : show line 2 in the form 10b5-1 −6,604 $90.79 $599,556 993,976 D
2026-09-01 Sale : show line 3 in the form 10b5-1 −63,596 $91.90 $5,844,237 930,380 D
2026-09-01 Sale : show line 4 in the form 10b5-1 −4,800 $92.44 $443,691 925,580 D
Open-market sales · 75,000 sh · avg $91.83 · $6,887,484

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-09-01 Exercise or conversion : show line 5 in the form 10b5-1 Employee Warrant (right to buy) −75,000 1,553,513 D
Loading xslF345X06/form4.xml…